A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Vinorelbine and Cisplatin in Untreated Advanced Non-Small Cell Lung Cancer
Publication Information Expand/Collapse
PMid: PMID29370458 | PMC number: PMC5963502
The association between ASCO Value framework and scientific and clinical impact of SWOG phase III clinical trials
PMid: PMID27986655 | PMC number: PMC5370550
PMid: PMID24559777 | PMC number: PMC3961058
PMid: PMID24627276 | PMC number: PMC3982777
Association between BMI at treatment initiation and cancer survival across multiple SWOG trials
PMid: PMID23910067 | PMC number: PMC4122504
PMid: PMID23669424 | PMC number: PMC4131693
Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials [PMID18202421]
Interim futility analysis with intermediate endpoints
The Southwest Oncology Group: progress in cancer research [PMID18929152]
Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer
PMid: PMID19073517 | PMC number: (Reviews are not within the scope of the Public Access)
Toxicity and survival by sex in patients with advanced non small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials.
Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions
Time from treatment to subsequent diagnosis of brain metastases in Stage III non-small cell lung cancer (NSCLC): a retrospective review by the Southwest Oncology Group (SWOG)
Molecular abnormalities of DNA damage and anti-microtubule response pathways in non-small cell lung carcinomas (NSCLC) from patients on the Southwest Oncology Group (SWOG) 9509 trial
Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small cell lung cancer
Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial
Tests for lifetime utility or cost via calibrating survival time
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial
Should older patients (PTS) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? an analysis of Southwest Oncology trials 9509 and 9308.
An economic analsis of Southwest Oncology Group trial S9509: Cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced nonsmall cell lung cancer
An economic analysis alongside a prospective randomized multicenter clinical trial of cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced non small cell lung cancer.
Current status of therapy for advanced non-small cell lung cancer: a perspective from the Southwest Oncology Group (SWOG)
A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial.